Clinical Trials Logo

Central Nervous System Neoplasms clinical trials

View clinical trials related to Central Nervous System Neoplasms.

Filter by:

NCT ID: NCT00003417 Completed - Clinical trials for Brain and Central Nervous System Tumors

Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme

Start date: September 1998
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Computer systems that allow doctors to create a 3-dimensional picture of the tumor in order to plan treatment may result in more effective radiation therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy that has been planned with a computer plus chemotherapy in treating patients who have glioblastoma multiforme.

NCT ID: NCT00003410 Completed - Clinical trials for Brain and Central Nervous System Tumors

Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas

Start date: July 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: New imaging procedures such as the use of gadolinium texaphyrin with MRI may improve the ability to detect the extent of gliomas. PURPOSE: Phase I trial to study the effectiveness of gadolinium texaphyrin used with MRI-guided surgery in treating patients with high-grade glioma.

NCT ID: NCT00003409 Completed - Clinical trials for Brain and Central Nervous System Tumors

Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Start date: July 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Motexafin gadolinium may increase the effectiveness of radiation therapy by making tumor cells more sensitive to radiation. PURPOSE: Phase I trial to study the effectiveness of motexafin gadolinium plus radiation therapy in treating patients who have newly diagnosed glioblastoma multiforme.

NCT ID: NCT00003375 Completed - Clinical trials for Brain and Central Nervous System Tumors

Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma

Start date: October 1998
Phase: Phase 2/Phase 3
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy combined with chemotherapy is more effective than radiation therapy alone in treating patients with low-grade glioma. PURPOSE: Phase II/III trial to evaluate observation and to compare the effectiveness of radiation therapy with or without combination chemotherapy in treating patients with low-grade glioma.

NCT ID: NCT00003372 Completed - Clinical trials for Brain and Central Nervous System Tumors

Topotecan in Treating Patients With Recurrent Brain Tumors

Start date: December 8, 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with recurrent brain tumor.

NCT ID: NCT00003348 Completed - Clinical trials for Brain and Central Nervous System Tumors

Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain

Start date: May 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of carmustine plus O(6)-benzylguanine in treating patients who have recurrent or progressive gliomas of the brain.

NCT ID: NCT00003309 Completed - Clinical trials for Brain and Central Nervous System Tumors

Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer

Start date: May 4, 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug and combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by radiation therapy in treating adult patients with brain cancer.

NCT ID: NCT00003304 Completed - Clinical trials for Brain and Central Nervous System Tumors

Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors

Start date: April 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients with recurrent oligodendroglial tumors following combination chemotherapy.

NCT ID: NCT00003301 Completed - Clinical trials for Brain and Central Nervous System Tumors

Irinotecan in Treating Patients With Recurrent Malignant Glioma

Start date: July 1998
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irinotecan in treating patients with recurrent malignant glioma.

NCT ID: NCT00003293 Completed - Clinical trials for Brain and Central Nervous System Tumors

SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme

Start date: February 1998
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether SU-101 is more effective than procarbazine in treating patients with glioblastoma multiforme. PURPOSE: Randomized phase III trial to compare the effectiveness of SU-101 with that of procarbazine in treating patients with glioblastoma multiforme that has recurred.